Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group

Simple item page
dc.contributor.authorÇelik G.E.
dc.contributor.authorAydın Ö.
dc.contributor.authorDamadoğlu E.
dc.contributor.authorBaççıoğlu A.
dc.contributor.authorÖzdemir S.K.
dc.contributor.authorBavbek S.
dc.contributor.authorEdiger D.
dc.contributor.authorErkekol F.Ö.
dc.contributor.authorGemicioğlu B.
dc.contributor.authorIşık S.R.
dc.contributor.authorKalpaklıoğlu A.F.
dc.contributor.authorKalyoncu A.F.
dc.contributor.authorKarakaya G.
dc.contributor.authorKeren M.
dc.contributor.authorMungan D.
dc.contributor.authorOğuzülgen İ.K.
dc.contributor.authorYıldız F.
dc.contributor.authorYılmaz İ.
dc.contributor.authorYorgancıoğlu A.
dc.date.accessioned2024-07-22T08:02:26Z
dc.date.available2024-07-22T08:02:26Z
dc.date.issued2023
dc.description.abstractIntroduction of inhaled corticosteroids (ICS) has been the cornerstone of the long-term management of asthma. ICSs either alone or in combination with long-acting beta-2 agonists have been shown to be associated with favorable asthma outcomes. However, asthma con-trol is still reported to be below expectations all around the world. Research in the last decades focusing on the use of ICS/formoterol both as maintenance and as needed (maintenance and reliever therapy approach) showed improved asthma outcomes. As a result of recent developments, Turkish Asthma Guidelines group aimed to revise asthma treatment recommendations. In general, we recommend physicians to consider the risk factors for poor asthma outcomes, patients’ compliance and expectations and then to determine “a personalized treatment plan.” Importantly, the use of short-acting beta-2 agonists alone as a symptom reliever in asthma patients not using regular ICS is no longer recommended. In stepwise treatment approach, we primarily recommend to use ICS-based controllers and initiate ICS as soon as possible. We define 2 different treatment tracks in stepwise approaches as maintenance and reliever therapy or fixed-dose therapy and equally recommend each track depending on the patient’s risks as well as decision of physicians in a personalized manner. For both tracks, a strong recommendation was made in favor of using add-on treatments before initiating phenotype-specific treatment in step 5. A strong recommendation was also made in favor of using biologic agents and/or aspirin treatment after desensitization in severe asthma when indicated. © Author(s).
dc.identifier.DOI-ID10.5152/ThoracResPract.2023.23035
dc.identifier.issn29799139
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/11863
dc.language.isoEnglish
dc.publisherAVES
dc.rightsAll Open Access; Gold Open Access
dc.subjectacetylsalicylic acid
dc.subjectallergen
dc.subjectazithromycin
dc.subjectbiological product
dc.subjectcorticosteroid
dc.subjectleukotriene receptor blocking agent
dc.subjectconsensus
dc.subjectcoughing
dc.subjectdesensitization
dc.subjectdisease exacerbation
dc.subjectdrug megadose
dc.subjectfollow up
dc.subjectforced expiratory volume
dc.subjectforced vital capacity
dc.subjecthuman
dc.subjectlow drug dose
dc.subjectmaintenance therapy
dc.subjectmedication compliance
dc.subjectphenotype
dc.subjectphysician
dc.subjectpractice guideline
dc.subjectprimary medical care
dc.subjectpulmonologist
dc.subjectReview
dc.subjectsevere asthma
dc.subjectTurkey (republic)
dc.titleStepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group
dc.typeReview

Files

Collections

Scopus Koleksiyonu